Megron-ER
Generic Name
Sumatriptan Succinate Extended-Release 50 mg Tablet
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| megron er 50 mg tablet | ৳ 50.00 | ৳ 500.00 |
Description
Overview of the medicine
Megron-ER 50 mg Tablet is an extended-release formulation containing Sumatriptan, used for the acute treatment of migraine attacks with or without aura in adults. It works by constricting blood vessels around the brain, thereby relieving migraine symptoms like headache, nausea, and sensitivity to light and sound.
Uses & Indications
Dosage
Adults
The usual dose is one 50 mg extended-release tablet taken with water as soon as migraine symptoms appear. Do not take a second dose within 24 hours. Maximum dose is one tablet in 24 hours.
Elderly
Use with caution in elderly patients; dosage adjustment may be necessary based on renal function.
Renal_impairment
No specific dose adjustment is recommended for patients with mild to moderate renal impairment. Use with caution in severe renal impairment.
How to Take
Take the tablet whole with water. Do not crush, chew, or split the tablet. It can be taken with or without food.
Mechanism of Action
Sumatriptan is a selective agonist for 5-hydroxytryptamine1 (5-HT1B/1D) receptors. It causes vasoconstriction of intracranial blood vessels, inhibits pro-inflammatory neuropeptide release from trigeminal nerve endings, and also has an effect on pain pathways in the brainstem, leading to relief of migraine headache.
Pharmacokinetics
Onset
Typically 30 minutes to 1 hour for immediate-release; longer for ER formulations (e.g., 1-2 hours for effect onset).
Excretion
Mainly excreted renally (approximately 60% as inactive metabolite, 20% as unchanged drug).
Half life
Approximately 2 hours for immediate-release; longer apparent half-life for ER due to sustained release (e.g., 4-6 hours).
Absorption
Rapidly absorbed after oral administration, with peak plasma concentrations achieved in approximately 2.5 hours for immediate-release and longer for extended-release formulations (e.g., 5-6 hours).
Metabolism
Primarily metabolized by monoamine oxidase A (MAO-A) to an inactive indole acetic acid analog.
Side Effects
Contraindications
- Ischemic heart disease (e.g., angina pectoris, history of myocardial infarction)
- Coronary artery vasospasm (Prinzmetal's angina)
- Uncontrolled hypertension
- History of stroke or transient ischemic attack (TIA)
- Severe hepatic impairment
- Concurrent use with ergotamine-containing preparations or other 5-HT1 agonists
- Concurrent use with MAO inhibitors or within 2 weeks of discontinuing an MAO inhibitor
Drug Interactions
SSRIs/SNRIs
Potential for serotonin syndrome. Monitor patients carefully.
MAO Inhibitors
Increased sumatriptan plasma levels due to reduced clearance. Contraindicated within 2 weeks of MAO inhibitor use.
Other 5-HT1 agonists (triptans)
Increased risk of vasospastic reactions. Do not use within 24 hours of sumatriptan.
Ergotamine-containing or ergot-type drugs
Increased risk of vasospastic reactions. Do not use within 24 hours of sumatriptan.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose may include convulsions, tremor, bradycardia, paralysis, and respiratory depression. Management is primarily supportive and symptomatic. Monitor cardiac function and vital signs.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. Sumatriptan is excreted into breast milk; caution should be exercised when administered to a nursing mother. It is recommended to discard breast milk for 12 hours after taking sumatriptan.
Side Effects
Contraindications
- Ischemic heart disease (e.g., angina pectoris, history of myocardial infarction)
- Coronary artery vasospasm (Prinzmetal's angina)
- Uncontrolled hypertension
- History of stroke or transient ischemic attack (TIA)
- Severe hepatic impairment
- Concurrent use with ergotamine-containing preparations or other 5-HT1 agonists
- Concurrent use with MAO inhibitors or within 2 weeks of discontinuing an MAO inhibitor
Drug Interactions
SSRIs/SNRIs
Potential for serotonin syndrome. Monitor patients carefully.
MAO Inhibitors
Increased sumatriptan plasma levels due to reduced clearance. Contraindicated within 2 weeks of MAO inhibitor use.
Other 5-HT1 agonists (triptans)
Increased risk of vasospastic reactions. Do not use within 24 hours of sumatriptan.
Ergotamine-containing or ergot-type drugs
Increased risk of vasospastic reactions. Do not use within 24 hours of sumatriptan.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose may include convulsions, tremor, bradycardia, paralysis, and respiratory depression. Management is primarily supportive and symptomatic. Monitor cardiac function and vital signs.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. Sumatriptan is excreted into breast milk; caution should be exercised when administered to a nursing mother. It is recommended to discard breast milk for 12 hours after taking sumatriptan.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 to 36 months from manufacturing date.
Availability
Pharmacies, hospitals, and clinics
Approval Status
Approved by FDA/DGDA
Patent Status
Generic available (patent expired for sumatriptan)
WHO Essential Medicine
YesClinical Trials
Sumatriptan has undergone numerous clinical trials demonstrating its efficacy and safety in the acute treatment of migraine. Extended-release formulations have also been studied for their sustained action.
Lab Monitoring
- No routine laboratory monitoring is generally required. However, ECG monitoring may be considered in patients with risk factors for coronary artery disease before prescribing sumatriptan.
Doctor Notes
- Assess cardiovascular risk factors before prescribing, especially in patients with multiple risk factors.
- Educate patients on the risk of medication overuse headache.
- Advise patients not to use for prophylactic treatment.
Patient Guidelines
- Take the medicine at the first sign of a migraine headache.
- Do not use for preventing migraines.
- Do not take more than one dose in 24 hours.
- Inform your doctor about all existing medical conditions and medications.
- Seek immediate medical attention if you experience severe chest pain, shortness of breath, or sudden vision changes.
Missed Dose Advice
Megron-ER is used for acute treatment, not for prevention. If a dose is missed for a migraine attack, take it as soon as remembered, but do not take more than one dose in 24 hours.
Driving Precautions
May cause drowsiness, dizziness, or vision disturbances. Patients should exercise caution when driving or operating machinery until they know how the medicine affects them.
Lifestyle Advice
- Identify and avoid migraine triggers (e.g., certain foods, stress, lack of sleep).
- Maintain a regular sleep schedule.
- Manage stress through relaxation techniques.
- Stay hydrated and eat balanced meals.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Megron-ER Brand
Other medicines available under the same brand name
